STX7 promotes EMT and tumor progression via NF-κB signaling, with a strong association to macrophage infiltration in cancers, including hepatocellular carcinoma, highlighting its potential as a prognostic biomarker and therapeutic target. Here, NFKB1 is linked to neoplasm.